Upper Gastrointestinal Safety with the Buffered Solution of Alendronate 70mg: Postmarketing Experience.

被引：0
|
作者：
Hruska, Josef [1 ]
Jorgensen, Flemming Kjaer [2 ]
Eriksen, Erik Fink [3 ]
机构：
[1] MeDACom GmbH, Bern, Switzerland
[2] KLIFO AS, Glostrup, Denmark
[3] Oslo Univ Hosp, Oslo, Norway
来源：
JOURNAL OF BONE AND MINERAL RESEARCH | 2017年 / 32卷
关键词：
OSTEOPOROSIS;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
SU0292
引用
收藏
页码：S269 / S269
页数：1
相关论文
共 50 条
  • [21] Upper gastrointestinal safety and tolerability of oral alendronate: A meta-analysis
    Zhou, Manru
    Zheng, Yayuan
    Li, Jin
    Wu, Jingkai
    Xu, Weiming
    Cui, Liao
    Yao, Weimin
    Liu, Yuyu
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2016, 11 (01) : 289 - 296
  • [22] A single zoledronic acid 5mg infusion is preferred over weekly 70mg oral alendronate in a clinical trial of postmenopausal women with osteoporosis/osteopenia
    Lindsay, R.
    Saag, K.
    Kriegman, A.
    Davis, J.
    Beamer, E.
    Zhou, W.
    OSTEOPOROSIS INTERNATIONAL, 2006, 17 : S240 - S240
  • [23] Clinical comparison in BMD gains with monthly oral ibandronate (150mg) and weekly oral alendronate (70mg): Results from the MOTION study
    Miller, P. D.
    Zerbini, C. A. F.
    Recker, R. R.
    Sedarati, F.
    Neate, C.
    Reginster, J. Y.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2007, 22 : S451 - S451
  • [24] Safety of once-weekly alendronate 70 mg in peridontal disease.
    Van Dyke, T
    Ryder, M
    Cordero, R
    Gallagher, A
    Griffiths, GR
    Offenbacher, S
    Cizza, G
    Shih, W
    Kimberlin, M
    Meng, L
    Lombardi, A
    ARTHRITIS AND RHEUMATISM, 2000, 43 (09): : S198 - S198
  • [25] Safety of once-weekly alendronate 70 mg in periodontal disease.
    Van Dyke, T
    Ryder, M
    Cordero, R
    Gallagher, A
    Griffiths, G
    Offenbacher, S
    Cizza, G
    Kimberlin, M
    Lombardi, A
    Meng, L
    Shih, W
    JOURNAL OF WOMENS HEALTH & GENDER-BASED MEDICINE, 2001, 10 (04): : 404 - 404
  • [26] Similar improvements in hip bone mineral density with monthly oral ibandronate (150mg) versus weekly oral alendronate (70mg) in postmenopausal osteoporosis
    Borges, J. L. C.
    Bolognese, M.
    Epstein, S.
    Sedarati, F.
    Neate, C.
    Miller, P. D.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2007, 22 : S326 - S326
  • [27] Upper gastrointestinal tolerability of once weekly alendronate 70 mg with concomitant non-steroidal anti-inflammatory drug use
    Cryer, B
    Miller, P
    Petruschke, RA
    Chen, E
    Geba, GP
    De Papp, AE
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2005, 21 (05) : 599 - 607
  • [28] A single zoledronic acid 5mg infusion is preferred over weekly 70mg oral alendronate in a clinical trial of postmenopausal women with osteoporosis/ osteopenia
    Lindsay, R.
    Saag, K.
    Kriegman, A.
    Davis, J.
    Beamer, E.
    Zhou, W.
    OSTEOPOROSIS INTERNATIONAL, 2006, 17 : S43 - S44
  • [29] Two-year clinical fracture experience with alendronate 70 mg once weekly
    Miller, P
    Recker, R
    Rosen, C
    Adami, S
    Meng, L
    Kaur, A
    Santora, A
    Orloff, J
    OSTEOPOROSIS INTERNATIONAL, 2002, 13 : S33 - S34
  • [30] Cost-effectiveness of buffered soluble alendronate 70 mg effervescent tablet for the treatment of postmenopausal women with osteoporosis in Italy
    M. Hiligsmann
    S. Maggi
    N. Veronese
    L. Sartori
    J.-Y. Reginster
    Osteoporosis International, 2021, 32 : 595 - 606
12345